HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HHS Supplement Report Conclusions Need Revision, Trade Groups Say

This article was originally published in The Tan Sheet

Executive Summary

Recent draft guidance issued by the USPSTF has supplement industry groups calling for revisions that will reflect a more positive light on nutritional ingredients and that won’t be misinterpreted by consumers.

You may also be interested in...

USPSTF Doesn’t See Forest Of VMS Benefits For Trees Of Reducing Cancer, Heart Disease Risks

US Preventative Services Task Force concludes evidence doesn't support  recommending VMS use to prevent cancer or cardiovascular disease. Trade groups and a natural medicine expert say task force's focus is narrow and its recommendation misleading. 

Larger Nutritional Studies Needed To Fill Data Gap – HHS Panel

USPSTF recommends expanded research and innovative methods to explore the effects and complexities of nutrients. The panel says current research is insufficient to determine whether the use of multivitamins and single-ingredient dietary supplements help prevent CVD or cancer, and recommends against the use of beta-carotene or vitamin E supplements for prevention of the conditions.

Vitamin A, C, E Supplements For CVD, Cancer Without Sufficient Evidence

"The evidence is insufficient to recommend for or against the use of supplements" containing vitamins A, C, or E and certain vitamin combinations for the prevention of cancer or cardiovascular disease, the U.S. Preventive Services Task Force has determined


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts